These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9926936)

  • 1. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features.
    Walker DR; Bond JP; Tarone RE; Harris CC; Makalowski W; Boguski MS; Greenblatt MS
    Oncogene; 1999 Jan; 18(1):211-8. PubMed ID: 9926936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants.
    Greenblatt MS; Beaudet JG; Gump JR; Godin KS; Trombley L; Koh J; Bond JP
    Oncogene; 2003 Feb; 22(8):1150-63. PubMed ID: 12606942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolutionary conservation and mutational spectrum of BMPR2 gene.
    Wong WK; Morse JH; Knowles JA
    Gene; 2006 Mar; 368():84-93. PubMed ID: 16361068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
    Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
    Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silent mutations in the gene encoding the p53 protein are preferentially located in conserved amino acid positions and splicing enhancers.
    Lamolle G; Marin M; Alvarez-Valin F
    Mutat Res; 2006 Aug; 600(1-2):102-12. PubMed ID: 16650445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.
    Martin AC; Facchiano AM; Cuff AL; Hernandez-Boussard T; Olivier M; Hainaut P; Thornton JM
    Hum Mutat; 2002 Feb; 19(2):149-64. PubMed ID: 11793474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
    Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
    Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
    Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
    Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
    Selivanova G; Wiman KG
    Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective pressures at a codon-level predict deleterious mutations in human disease genes.
    Arbiza L; Duchi S; Montaner D; Burguet J; Pantoja-Uceda D; Pineda-Lucena A; Dopazo J; Dopazo H
    J Mol Biol; 2006 May; 358(5):1390-404. PubMed ID: 16584746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
    Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
    Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
    Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural assessment of single amino acid mutations: application to TP53 function.
    Yip YL; Zoete V; Scheib H; Michielin O
    Hum Mutat; 2006 Sep; 27(9):926-37. PubMed ID: 16917930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guinea pig p53 mRNA: identification of new elements in coding and untranslated regions and their functional and evolutionary implications.
    D'erchia AM; Pesole G; Tullo A; Saccone C; Sbisà E
    Genomics; 1999 May; 58(1):50-64. PubMed ID: 10331945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temperature-sensitive mutants of p53 associated with human carcinoma of the lung.
    Medcalf EA; Takahashi T; Chiba I; Minna J; Milner J
    Oncogene; 1992 Jan; 7(1):71-6. PubMed ID: 1741167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phylogenetic approach to assessing the significance of missense mutations in disease genes.
    Santibáñez Koref MF; Gangeswaran R; Santibáñez Koref IP; Shanahan N; Hancock JM
    Hum Mutat; 2003 Jul; 22(1):51-8. PubMed ID: 12815593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.
    Bullock AN; Henckel J; Fersht AR
    Oncogene; 2000 Mar; 19(10):1245-56. PubMed ID: 10713666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of tetramerization in p53 function.
    Chène P
    Oncogene; 2001 May; 20(21):2611-7. PubMed ID: 11420672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.